Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform.
Sanyou Bio is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs.
Both parties will leverage their respective expertise in
generative AI technology and practical experience of drug development
from target discovery to Investigational New Drug (IND) application, to
create a next-generation antibody drug discovery platform driven by AIGC
and jointly promote trilateral cooperation with leading innovative
pharmaceutical companies or biotechs to enhance the efficiency of new
drug R&D and help pharmaceutical R&D enterprises improve global
competitiveness.
In this strategic cooperation, Sanyou Bio will integrate
BioGeometry’s proprietary generative AI antibody design platform
(GeoBiologics). Both parties will invest their respective advantageous
resources, professional technologies and experiences to create an
outstanding Dry-Wet antibody R&D platform by integrating
BioGeometry‘s leading AI algorithm dry lab platform with Sanyou Bio’s
wet lab capabilities. This platform will be utilized for the development
of more large molecule drug pipelines and the incubation of innovative
projects, paving the way for further market expansion.
Sanyou has built a world-leading high-throughput, and integrated
R&D platform for innovative antibody drugs, accumulating and forming
the world’s largest antibody library and other technical resources. The
antibody library construction platform, based on nine super-trillion
antibody libraries as its core, has a capacity of up to 10 trillion. It
seamlessly integrates phage display and mammalian cell protein
expression of molecule generation technologies. Equipped with fully
automated screening and integrated antibody drug R&D capabilities,
it is suitable for challenging innovative targets and the development of
high-difficulty new molecules, with a focus on generating molecules
with characteristics such as “close to natural, high affinity, and
excellent developability”. The platform has strong wet experimental
capabilities and data advantages.
As a leading AI-driven protein design enterprise, BioGeometry has
developed atomic-level geometric deep learning models which learn from
massive data to effectively save the time and costs in antibody design,
improve economic efficiency and success rates. Moreover, BioGeometry has
achieved a closed-loop between dry and wet lab on its generative AI
antibody discovery SaaS platform, GeoBiologics. Molecules generated or
optimized by AI models are further validated and screened through
high-throughput wet-lab experiments.
At the same time, the experimental data is fed back to the AI
models to enhance prediction accuracy and confidence. Through multiple
rounds of AI design and wet-lab validation, functional molecules can be
discovered more efficiently.
Dr. Guojun Lang, founder and CEO of Sanyou Bio, remarked:
“BioGeometry’s generative AI technology has enabled Sanyou to achieve
intelligent and digital transformation of our antibody drug R&D
platform, further strengthening our advantages in new drug discovery and
preclinical integration. We believe that the AIGC antibody drug
discovery platform created through our collaboration with BioGeometry
will provide more innovative solutions for new drug R&D enterprises,
accelerate the preclinical research of more new drugs, and even
facilitate their entry into clinical trials, thereby enhancing global
competitiveness of pharmaceutical R&D enterprises.”
Dr. Jian Tang, founder and CEO of BioGeometry, stated: “We look
forward to jointly creating with Sanyou Bio a cutting-edge AI-enabled
antibody discovery platform combining dry and wet labs. This platform
aims to become an innovative model for AI-empowered new drug R&D
leading the industry, and accelerate the development of antibody drug
R&D and fully enter the era of artificial intelligence. We hope to
incubate and advancing more large-molecule drug pipelines through our
platform, jointly overcoming more challenges in antibody drug R&D,
and making substantive contributions to the progress of global disease
treatment.”
About BioGeometry
BioGeometry is a generative AI-driven protein design and R&D
platform company committed to providing biomanufacturing solutions to
traditional manufacturing industries, achieving green and intelligent
transformation. The company constructs generative artificial
intelligence (AIGC) large-models to understand the language of life,
building multimodal large-models that bridge natural language and
protein language to reinvent the process of protein drug discovery and
design. Dedicated to creating programmable proteins, BioGeometry applies
these innovations in biopharmaceuticals and biomaterial production. By
applying their expertise to drug development, BioGeometry addresses
traditional challenges in large-molecule drug manufacturing, such as
high costs, lengthy processes, low success rates, and difficulties in
formulation, thus offering innovative drugs to save patients' lives.
Founded in 2022 by Dr. Jian Tang, a renowned scientist in AI4Drug
and deep learning on graphs, with Turing Award laureate Yoshua Bengio
serving as the chief scientific advisor, the company has built two
foundational platforms: an AI-driven large molecule drug design platform
and high-throughput wet-lab validation, creating a closed-loop system
that empowers partners to achieve precise and efficient large molecule
drug design and optimization.
Business Cooperation: bd@biogeom.com
Official Website: www.biogeom.com
About Sanyou Bio
Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech
biotechnology enterprise focusing on R&D and services of innovative
biologic drugs. Sanyou has built the 4C business patterns that integrate
"differentiated CRO, integrated CDO, innovative CPO and characteristic
CRS”, to accomplish the mission “to make the R&D easy for innovative
biologics”.
Sanyou has established an integrated innovative biologic drug
R&D laboratory with advanced facilities, and has a professional team
with the majority holding a Ph.D. or master degree. Sanyou has built
three industry-leading innovative technology platforms featured by
“super-trillion, integration, and intelligence" , which are comprised of
more than 50 sub-platforms with the core innovative super-trillion
phage display platform, and supported by platforms of material
preparation, biologics discovery, molecule optimization, in vitro and in
vivo efficacy, production cell line construction, upstream and
downstream process development, preclinical R&D, industrialization
development, etc.
Sanyou’s business network has expanded to all parts of the world,
including Asia, US and Europe, and established branches in Boston,
Philadelphia, San Diego and London. Sanyou has established friendly
business relationships with more than 1000 pharmaceutical companies,
drug R&D institutions and diagnostics companies worldwide. Sanyou
received National-level certification as a high-tech enterprise and a
Specialized and Sophisticated enterprise, and passed the ISO9001 quality
assurance certification and GB/T intellectual property management
system certification.
Business Cooperation: service@sanyoubio.com
Official Website: www.sanyoubio.com